Publications
FDA turmoil reshapes biotech dealmaking terms
Quoted, Axios
Shareholder Chris Simpson discusses how ongoing uncertainty and instability at the FDA is reshaping the structure and negotiation of biotech and pharma deals.
(subscription required)